These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Pfizer Inc. Bextra valdecoxib NCT00649610 Pain, Acute Phase IV Bextra is no longer marketed in the United States Clinical Study Summary Protocol No. A3471012: Randomized, double blind, multicenter study of the safety and efficacy of valdecoxib 40 mg once daily vs. diclofenac 75mg twice daily in subjects with acute low back pain. Link to ClinicalTrials.gov Registration: http://www.clinicaltrials.gov/ct2/show/NCT00649610?term=a3471012&rank=1 Pfizer will use reasonable efforts to include accurate and up-to-date information on the ClinicalStudyResults.org web site. However, because the status of studies often changes, Pfizer can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. You agree that access to and use of information posted by Pfizer on the ClinicalStudyResults.org web site is at your own risk. Pfizer disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Pfizer shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Pfizer on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. The ClinicalStudyResults.org web site is maintained by PhRMA, a trade association of which Pfizer is a member. PhRMA had no role in the sponsorship or conduct of the studies posted by Pfizer on ClinicalStudyResults.org. Company Study Protocol No. A3471012 Back to Search Results